171 related articles for article (PubMed ID: 35659704)
1. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.
Saad M; Lee SJ; Tan AC; El Naqa IM; Hodi FS; Butterfield LH; LaFramboise WA; Storkus W; Karunamurthy AD; Conejo-Garcia J; Hwu P; Streicher H; Sondak VK; Kirkwood JM; Tarhini AA
J Transl Med; 2022 Jun; 20(1):253. PubMed ID: 35659704
[TBL] [Abstract][Full Text] [Related]
2. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
McLouth LE; Zheng Y; Smith S; Hodi FS; Rao UN; Cohen GI; Amatruda TT; Dakhil SR; Curti BD; Nakhoul I; Chandana SR; Bane CL; Marinier DE; Lee SJ; Sondak VK; Kirkwood JM; Tarhini AA; Wagner LI
Qual Life Res; 2023 Jan; 32(1):183-196. PubMed ID: 36029412
[TBL] [Abstract][Full Text] [Related]
4. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
Tarhini AA; Lee SJ; Tan AC; El Naqa IM; Stephen Hodi F; Butterfield LH; LaFramboise WA; Storkus WJ; Karunamurthy AD; Conejo-Garcia JR; Hwu P; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074904
[TBL] [Abstract][Full Text] [Related]
5. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Tarhini AA; Kang N; Lee SJ; Hodi FS; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963015
[TBL] [Abstract][Full Text] [Related]
6. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.
Tarhini AA; Lee SJ; Li X; Rao UNM; Nagarajan A; Albertini MR; Mitchell JW; Wong SJ; Taylor MA; Laudi N; Truong PV; Conry RM; Kirkwood JM
Clin Cancer Res; 2019 Jan; 25(2):524-532. PubMed ID: 30420448
[TBL] [Abstract][Full Text] [Related]
7. CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
Khunger A; Piazza E; Warren S; Smith TH; Ren X; White A; Elliott N; Cesano A; Beechem JM; Kirkwood JM; Tarhini AA
PLoS One; 2021; 16(1):e0245287. PubMed ID: 33428680
[TBL] [Abstract][Full Text] [Related]
8. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Larkin J; Del Vecchio M; Mandalá M; Gogas H; Arance Fernandez AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Marquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; Lutzky J; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill AG; Fecher LA; Millward M; Nathan PD; Khushalani NI; Queirolo P; Ritchings C; Lobo M; Askelson M; Tang H; Dolfi S; Ascierto PA; Weber J
Clin Cancer Res; 2023 Sep; 29(17):3352-3361. PubMed ID: 37058595
[TBL] [Abstract][Full Text] [Related]
10. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.
Bresler SC; Min L; Rodig SJ; Walls AC; Xu S; Geng S; Hodi FS; Murphy GF; Lian CG
Lab Invest; 2017 Feb; 97(2):207-216. PubMed ID: 27918555
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.
Unger JM; Darke A; Othus M; Truong TG; Khushalani N; Kendra K; Lewis KD; Faller B; Funchain P; Buchbinder EI; Tarhini AA; Kirkwood JM; Sharon E; Sondak V; Guild SR; Grossmann K; Ribas A; Patel SP
JAMA Oncol; 2023 Feb; 9(2):251-260. PubMed ID: 36416836
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.
Eggermont AM
Eur J Cancer; 2016 Dec; 69():39-42. PubMed ID: 27816830
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
Minutilli E; Feliciani C
Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
Khushalani NI; Vassallo M; Goldberg JD; Eroglu Z; Kim Y; Cao B; Ferguson R; Monson KR; Kirchhoff T; Amato CM; Burke P; Strange A; Monk E; Gibney GT; Kudchadkar R; Markowitz J; Brohl AS; Pavlick A; Richards A; Woods DM; Weber J
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450385
[TBL] [Abstract][Full Text] [Related]
18. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
[TBL] [Abstract][Full Text] [Related]
19. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
Mozzillo N; Ascierto P
Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
Tarhini A; Lin Y; Lin H; Rahman Z; Vallabhaneni P; Mendiratta P; Pingpank JF; Holtzman MP; Yusko EC; Rytlewski JA; Rao UNM; Ferris RL; Kirkwood JM
J Immunother Cancer; 2018 Oct; 6(1):112. PubMed ID: 30352626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
